The DLG1 Knockout A2780 Polyclonal Cells are a genetically heterogeneous pool of human ovarian carcinoma A2780 cells engineered via CRISPR/Cas9-mediated disruption of the DLG1 locus. This polyclonal knockout population serves as a loss-of-function model to investigate the roles of the DLG1 scaffold protein in epithelial cancer biology. Unlike monoclonal lines, this product preserves natural cell-to-cell variation, facilitating studies that require population-level responses to genetic perturbation.
The host cell line A2780 is a well-characterized model of ovarian endometrioid adenocarcinoma, originally established from an untreated patient. It is extensively employed in cancer research to study mechanisms of platinum-based chemotherapy sensitivity, tumor progression, and hormone responsiveness. The epithelial nature of A2780 cells makes them particularly suitable for dissecting cell junction dynamics and apicobasal polarity pathways disrupted in malignancy.
As a membrane-associated guanylate kinase (MAGUK) family scaffold, DLG1 orchestrates multi-protein complexes at adherens and tight junctions. It interacts with key polarity regulators including APC, beta-catenin, and LGN/GPSM2, while linking adhesion receptors such as E-cadherin to downstream effectors like PTEN, Akt, and ERK. DLG1 is regulated by upstream kinases including Src family kinases, Cdk5, and PKA. Knockout of DLG1 relieves constraints on Wnt/beta-catenin and Hippo/YAP signaling, thereby altering transcriptional programs that control proliferation, migration, and apoptosis.
In A2780 ovarian cancer cells, disruption of DLG1 is expected to perturb junctional integrity and enhance oncogenic signaling cascades, providing a relevant context to explore how scaffold protein loss contributes to ovarian carcinoma progression and drug resistance. The polyclonal nature of the knockout pool allows for the examination of heterogeneous cellular responses, reflecting the diversity seen in tumor cell populations. This model is particularly useful for interrogating crosstalk between adhesion complexes and growth factor signaling networks that drive aggressive cancer phenotypes.
Researchers can utilize these DLG1 knockout polyclonal cells in a variety of assays to assess cell polarity, adhesion, signal transduction, and therapeutic sensitivity. Typical applications include western blotting for junctional and signaling proteins, immunofluorescence imaging of tight and adherens junctions, cell proliferation and Transwell migration assays, apoptosis analysis by flow cytometry, co-immunoprecipitation of DLG1-associated complexes, and transcriptomic profiling via RNA-seq. The cells are also compatible with high-throughput drug sensitivity screening to identify vulnerabilities associated with DLG1 loss. For additional information or technical support, please contact Ascent Research.
